{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T23:58:52Z","timestamp":1793923132826,"version":"4.8.0"},"reference-count":188,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,1,25]],"date-time":"2023-01-25T00:00:00Z","timestamp":1674604800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,1,25]],"date-time":"2023-01-25T00:00:00Z","timestamp":1674604800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1007\/s11033-023-08283-x","type":"journal-article","created":{"date-parts":[[2023,1,25]],"date-time":"2023-01-25T07:02:56Z","timestamp":1674630176000},"page":"3815-3833","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":53,"title":["Molecular and therapeutic insights of rapamycin: a multi-faceted drug from Streptomyces hygroscopicus"],"prefix":"10.1007","volume":"50","author":[{"given":"Sanjeev K.","family":"Ganesh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1828-8212","authenticated-orcid":false,"given":"C.","family":"Subathra Devi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,25]]},"reference":[{"key":"8283_CR1","first-page":"467","volume-title":"Bioactive compounds of Streptomyces: biosynthesis to applications. Studies in natural products chemistry","author":"R Salwan","year":"2020","unstructured":"Salwan R, Sharma V (2020) Bioactive compounds of Streptomyces: biosynthesis to applications. Studies in natural products chemistry. Elsevier BV, Netherlands, pp 467\u2013491"},{"key":"8283_CR2","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s10534-011-9506-6","volume":"25","author":"S Sadhasivam","year":"2012","unstructured":"Sadhasivam S, Shanmugam P, Veerapandian M, Subbiah R, Yun K (2012) Biogenic synthesis of multidimensional gold nanoparticles assisted by Streptomyces hygroscopicus and its electrochemical and antibacterial properties. Biometals 25:351\u2013360. https:\/\/doi.org\/10.1007\/s10534-011-9506-6","journal-title":"Biometals"},{"key":"8283_CR3","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/j.tetlet.2011.11.115","volume":"53","author":"Y Igarashi","year":"2012","unstructured":"Igarashi Y, Asano D, Furihata K, Oku N, Miyanaga S, Sakurai H et al (2012) Absolute configuration of pterocidin, a potent inhibitor of tumor cell invasion from a marine-derived Streptomyces. Tetrahedron Lett 53:654\u2013656. https:\/\/doi.org\/10.1016\/j.tetlet.2011.11.115","journal-title":"Tetrahedron Lett"},{"key":"8283_CR4","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/ja.2006.28","volume":"59","author":"Y Igarashi","year":"2006","unstructured":"Igarashi Y, Miura SS, Fujita T, Furumai T (2006) Pterocidin, a cytotoxic compound from the endophytic Streptomyces hygroscopicus. J Antibiot 59:193\u2013195. https:\/\/doi.org\/10.1038\/ja.2006.28","journal-title":"J Antibiot"},{"key":"8283_CR5","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.cmet.2014.01.001","volume":"4","author":"J Li","year":"2014","unstructured":"Li J, Kim SG, Blenis J (2014) Rapamycin: one drug, many effects. Cell Metab 4:373\u2013379. https:\/\/doi.org\/10.1016\/j.cmet.2014.01.001","journal-title":"Cell Metab"},{"key":"8283_CR6","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1099\/00221287-137-2-351","volume":"137","author":"O Hara","year":"1991","unstructured":"Hara O, Murakami T, Imai S, Anzai H, Itoh R, Kumada Y (1991) The bialaphos biosynthetic genes of Streptomyces viridochromogenes: cloning, heterospecific expression, and comparison with the genes of Streptomyces hygroscopicus. J Gen Microbiol 137:351\u2013359. https:\/\/doi.org\/10.1099\/00221287-137-2-351","journal-title":"J Gen Microbiol"},{"key":"8283_CR7","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/s10295-016-1834-7","volume":"44","author":"YJ Yoo","year":"2017","unstructured":"Yoo YJ, Kim H, Park SR, Yoon YJ (2017) An overview of rapamycin: from discovery to future perspectives. J Ind Microbiol Biotechnol 44:537\u201353. https:\/\/doi.org\/10.1007\/s10295-016-1834-7","journal-title":"J Ind Microbiol Biotechnol"},{"key":"8283_CR8","doi-asserted-by":"publisher","first-page":"721","DOI":"10.7164\/antibiotics.28.727","volume":"28","author":"SN Sehgal","year":"1975","unstructured":"Sehgal SN, Baker H, V\u00e9zina C (1975) Rapamycin (Ay-22,989), a new antifungal antibiotic. II. fermentation, isolation and characterization. J Antibiot 28:721\u2013726. https:\/\/doi.org\/10.7164\/antibiotics.28.727","journal-title":"J Antibiot"},{"key":"8283_CR9","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1111\/j.1432-2277.2004.00039.x","volume":"18","author":"SCJ Chueh","year":"2005","unstructured":"Chueh SCJ, Kahan BD (2005) Clinical application of sirolimus in renal transplantation: an update. Transpl Int 18:261\u201377. https:\/\/doi.org\/10.1111\/j.1432-2277.2004.00039.x","journal-title":"Transpl Int"},{"key":"8283_CR10","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s10295-016-1880-1","volume":"44","author":"L Dang","year":"2017","unstructured":"Dang L, Liu J, Wang C, Liu H, Wen J (2017) Enhancement of rapamycin production by metabolic engineering in Streptomyces hygroscopicus based on genome-scale metabolic model. J Ind Microbiol Biotechnol 44:259\u2013270. https:\/\/doi.org\/10.1007\/s10295-016-1880-1","journal-title":"J Ind Microbiol Biotechnol"},{"key":"8283_CR11","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.jhep.2010.10.044","volume":"55","author":"E Patsenker","year":"2011","unstructured":"Patsenker E, Schneider V, Ledermann M, Saegesser H, Dorn C, Hellerbrand C (2011) Potent antifibrotic activity of mTOR inhibitors sirolimus and everolimus but not of cyclosporine A and tacrolimus in experimental liver fibrosis. J Hepatol 55:388\u2013398. https:\/\/doi.org\/10.1016\/j.jhep.2010.10.044","journal-title":"J Hepatol"},{"key":"8283_CR12","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1007\/s10529-005-8463-y","volume":"27","author":"ZN Xu","year":"2005","unstructured":"Xu ZN, Shen WH, Chen XY, Lin JP, Cen PL (2005) A high-throughput method for screening of rapamycin-producing strains of Streptomyces hygroscopicus by cultivation in 96-well microtiter plates. Biotechnol Lett 27:1135\u20131140. https:\/\/doi.org\/10.1007\/s10529-005-8463-y","journal-title":"Biotechnol Lett"},{"key":"8283_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-019-11174-0","volume":"10","author":"KH Schreiber","year":"2019","unstructured":"Schreiber KH, Arriola ASI, Yu D, Brinkman JA, Velarde MC, Syed FA (2019) A novel rapamycin analog is highly selective for mTORC1 in-vivo. Nat Commun 10:1\u20132. https:\/\/doi.org\/10.1038\/s41467-019-11174-0","journal-title":"Nat Commun"},{"key":"8283_CR14","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1002\/eji.1830250239","volume":"25","author":"DA Fruman","year":"1995","unstructured":"Fruman DA, Wood MA, Gjertson CK, Katz HR, Burakoff SJ, Bierer BE (1995) FK506 binding protein 12 mediates sensitivity to both FK506 and rapamycin in murine mast cells. Eur J Immunol 25:563\u2013571. https:\/\/doi.org\/10.1002\/eji.1830250239","journal-title":"Eur J Immunol"},{"key":"8283_CR15","doi-asserted-by":"publisher","first-page":"4159","DOI":"10.1158\/0008-5472.CAN-08-4645","volume":"69","author":"AR Raimondi","year":"2009","unstructured":"Raimondi AR, Molinolo A, Gutkind JS (2009) Rapamycin prevents early onset of tumorigenesis in an oral-specific K-ras and p53 two-hit carcinogenesis model. Clin Cancer Res 69:4159\u20134166. https:\/\/doi.org\/10.1158\/0008-5472.CAN-08-4645","journal-title":"Clin Cancer Res"},{"key":"8283_CR16","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/0968-0004(93)90069-y","volume":"18","author":"J Kunz","year":"1993","unstructured":"Kunz J, Hall MN (1993) Cyclosporin A, FK506 and rapamycin: more than just immunosuppression. Trends Biochem Sci 18:334\u2013338. https:\/\/doi.org\/10.1016\/0968-0004(93)90069-y","journal-title":"Trends Biochem Sci"},{"key":"8283_CR17","doi-asserted-by":"publisher","first-page":"330","DOI":"10.7150\/ijbs.4.330","volume":"4","author":"B Prapagdee","year":"2008","unstructured":"Prapagdee B, Kuekulvong C, Mongkolsuk S (2008) Antifungal potential of extracellular metabolites produced by Streptomyces hygroscopicus against phytopathogenic fungi. Int J Biol Sci 4:330\u2013337. https:\/\/doi.org\/10.7150\/ijbs.4.330","journal-title":"Int J Biol Sci"},{"key":"8283_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12934-021-01561-y","volume":"20","author":"P Wang","year":"2021","unstructured":"Wang P, Yin Y, Wang X, Wen J (2021) Enhanced ascomycin production in Streptomyces hygroscopicus var. Ascomyceticus by employing polyhydroxybutyrate as an intracellular carbon reservoir and optimizing carbon addition. Microb Cell Factories 20:1\u20136. https:\/\/doi.org\/10.1186\/s12934-021-01561-y","journal-title":"Microb Cell Factories"},{"key":"8283_CR19","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s00253-016-7886-9","volume":"101","author":"SMA Lima","year":"2017","unstructured":"Lima SMA (2017) Characterization of the biochemical, physiological, and medicinal properties of Streptomyces hygroscopicus ACTMS-9H isolated from the Amazon (Brazil). Appl Microbiol Biotechnol 101:711\u2013723. https:\/\/doi.org\/10.1007\/s00253-016-7886-9","journal-title":"Appl Microbiol Biotechnol"},{"key":"8283_CR20","doi-asserted-by":"publisher","first-page":"694","DOI":"10.7164\/antibiotics.53.694","volume":"53","author":"K Nonaka","year":"2000","unstructured":"Nonaka K, Tsukiyama T, Okamoio Y, Sato K, Kumasaka C, Yamamoto T, Maruyama F, Yoshikawa H (2000) New milbemycins from Streptomyces hygroscopicus subsp. aureolacrimosus: fermentation, isolation and structure elucidation. J Antibiot 53:694\u2013704. https:\/\/doi.org\/10.7164\/antibiotics.53.694","journal-title":"J Antibiot"},{"key":"8283_CR21","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1021\/np050272l","volume":"68","author":"P Cai","year":"2005","unstructured":"Cai P, Kong F, Ruppen ME, Glasier G, Carter GT (2005) Hygrocins A and B, naphthoquinone macrolides from Streptomyces hygroscopicus. J Nat Prod 68:1736\u20131742. https:\/\/doi.org\/10.1021\/np050272l","journal-title":"J Nat Prod"},{"key":"8283_CR22","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1021\/np50047a016","volume":"49","author":"RM Heisey","year":"1986","unstructured":"Heisey RM, Putnam AR (1986) Herbicidal effects of geldanamycin and nigericin, antibiotics from Streptomyces hygroscopicus. J Nat Prod 49:859\u2013865. https:\/\/doi.org\/10.1021\/np50047a016","journal-title":"J Nat Prod"},{"key":"8283_CR23","doi-asserted-by":"publisher","first-page":"9","DOI":"10.7164\/antibiotics.45.1433","volume":"45","author":"K Sugawara","year":"1992","unstructured":"Sugawara K, Nlshiyama Y, Toda S, Komiyama N, Hatori M, Moriyama T et al (1992) Lactimidomycin\u2021 a new glutarimide group antibiotic production, isolation, structure and biological activity. J Antibiot 45:9. https:\/\/doi.org\/10.7164\/antibiotics.45.1433","journal-title":"J Antibiot"},{"key":"8283_CR24","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.7164\/antibiotics.23.442","volume":"23","author":"C Deboer","year":"1970","unstructured":"Deboer C, Meulman PA, Wnuk RJ, Peterson DH (1970) Geldanamycin, a new antibiotic. J Antibiot 23:1433\u20131441. https:\/\/doi.org\/10.7164\/antibiotics.23.442","journal-title":"J Antibiot"},{"key":"8283_CR25","doi-asserted-by":"publisher","DOI":"10.7164\/antibiotics.31.77-14","author":"A Imada","year":"1978","unstructured":"Imada A, Nozaki Y, Hasegawa T, Igarasi S, Yoneda M, Mizuta E (1978) Carriomycin, a new polyether antibiotic produced by Streptomyces hygroscopicus. J Antibiot. https:\/\/doi.org\/10.7164\/antibiotics.31.77-14","journal-title":"J Antibiot"},{"key":"8283_CR26","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.7164\/antibiotics.29.1182","volume":"29","author":"C Deboer","year":"1976","unstructured":"Deboer C, Dietz A (1976) The description and antibiotic production of Streptomyces hygroscopicus var. Geldanus. J Antibiot 29:1182\u20138. https:\/\/doi.org\/10.7164\/antibiotics.29.1182","journal-title":"J Antibiot"},{"key":"8283_CR27","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1128\/AAC.47.1.62-69.2003","volume":"47","author":"MP Singh","year":"2003","unstructured":"Singh MP, Petersen PJ, Weiss WJ, Janso JE, Luckman SW, Lenoy EB (2003) Mannopeptimycins, new cyclic glycopeptide antibiotics produced by Streptomyces hygroscopicus LL-AC98: antibacterial and mechanistic activities. Antimicrob Agents Chemother 47:62\u20139","journal-title":"Antimicrob Agents Chemother"},{"key":"8283_CR28","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1128\/am.22.3.303-308.1971","volume":"22","author":"LE Johnson","year":"1971","unstructured":"Johnson LE, Dietz A (1971) Scopafungin, a crystalline antibiotic produced by Streptomyces hygroscopicus var. Enhygrus var. Nova. Appl Microbiol 22:303\u2013308. https:\/\/doi.org\/10.1128\/am.22.3.303-308.1971","journal-title":"Appl Microbiol"},{"key":"8283_CR29","doi-asserted-by":"publisher","first-page":"340","DOI":"10.7164\/antibiotics.32.255","volume":"52","author":"T Fukai","year":"1999","unstructured":"Fukai T, Kuroda J, Nomura T, Jun U, Akao M (1999) Skeletal structure of neocopiamycin B from Streptomyces hygroscopicus var. Crystallogenes. J Antibiot 52:340\u2013344. https:\/\/doi.org\/10.7164\/antibiotics.32.255","journal-title":"J Antibiot"},{"key":"8283_CR30","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1080\/00021369.1979.10863695","volume":"43","author":"H Matsui","year":"1979","unstructured":"Matsui H, Sato K, Enei H, Hirose Y (1979) Production of guanosine by psicofuranine and decoyinine resistant mutants of Bacillus subtilis. Agric Biol Chem 43:1739\u20131744. https:\/\/doi.org\/10.1080\/00021369.1979.10863695","journal-title":"Agric Biol Chem"},{"key":"8283_CR31","doi-asserted-by":"publisher","first-page":"255","DOI":"10.7164\/antibiotics.32.255","volume":"32","author":"S Omura","year":"1979","unstructured":"Omura S, Iwai Y, Takahashi Y, Sadakane N, Nakagawa A, Oiwa H (1979) Herbimycin, a new antibiotic produced by a strain of Streptomyces. J Antibiot 32:255\u2013261","journal-title":"J Antibiot"},{"key":"8283_CR32","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s12010-009-8629-5","volume":"158","author":"V Gesheva","year":"2009","unstructured":"Gesheva V (2009) Optimization of the production medium for biosynthesis of antifungal antibiotic Ak-111-81 by phosphate-deregulated mutant of Streptomyces hygroscopicus. Appl Biochem Biotechnol 158:20\u201324. https:\/\/doi.org\/10.1007\/s12010-009-8629-5","journal-title":"Appl Biochem Biotechnol"},{"key":"8283_CR33","doi-asserted-by":"publisher","first-page":"627","DOI":"10.7164\/antibiotics.53.627","volume":"53","author":"V Ivanova","year":"2000","unstructured":"Ivanova V, Gesheva V, Kolarova M (2000) Dihydroniphimycin: New polyol macrolide antibiotic produced by Streptomyces hygroscopicus 15. Isolation and structure elucidation. J Antibiot 53:627\u2013632. https:\/\/doi.org\/10.7164\/antibiotics.53.627","journal-title":"J Antibiot"},{"key":"8283_CR34","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1271\/bbb.65.1252","volume":"65","author":"M Uyeda","year":"2001","unstructured":"Uyeda M, Mizukami M, Yokomizo K, Suzuki K (2001) Pentalenolactone I and hygromycin A, immunosuppressants produced by Streptomyces filipinensis and Streptomyces hygroscopicus. Biosci Biotechnol Biochem 65:1252\u20131254. https:\/\/doi.org\/10.1271\/bbb.65.1252","journal-title":"Biosci Biotechnol Biochem"},{"key":"8283_CR35","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.chembiol.2006.05.013","volume":"13","author":"N Palaniappan","year":"2006","unstructured":"Palaniappan N, Ayers S, Gupta S, Habib ES, Reynolds KA (2006) Production of hygromycin A analogs in Streptomyces hygroscopicus NRRL 2388 through identification and manipulation of the biosynthetic gene cluster. Chem Biol 13:753\u201364","journal-title":"Chem Biol"},{"key":"8283_CR36","doi-asserted-by":"publisher","first-page":"293","DOI":"10.7164\/antibiotics.44.293","volume":"44","author":"M Nakajima","year":"1991","unstructured":"Nakajima M, Itoi K, Takamatsu Y, Kinoshita T, Okazaki T, Kawakubo K (1991) Hydantocidin: a new compound with herbicidal activity from Streptomyces hygroscopicus. J Antibiot 44:293\u2013300. https:\/\/doi.org\/10.7164\/antibiotics.44.293","journal-title":"J Antibiot"},{"key":"8283_CR37","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1080\/00021369.1991.10870694","volume":"55","author":"H Kato","year":"1991","unstructured":"Kato H, Nagayama K, Abe H, Kobayashi R, Ishihara E (1991) Isolation, structure and biological activity of trialaphos. Agric Biol Chem 55:1133\u20131134. https:\/\/doi.org\/10.1080\/00021369.1991.10870694","journal-title":"Agric Biol Chem"},{"key":"8283_CR38","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1021\/jf00046a043","volume":"42","author":"MG Nair","year":"1994","unstructured":"Nair MG, Thorogood DL, Chandra A, Ammermann E, Walker N, Kiehs K (1994) Gopalamicin, an antifungal macrodiolide produced by Soil Actinomycetes. J Agric Food Chem 42:2308\u20132310","journal-title":"J Agric Food Chem"},{"key":"8283_CR39","first-page":"1","volume-title":"Marine Microbiology: Bioactive Compounds and Biotechnological Applications","author":"R Anandan","year":"2016","unstructured":"Anandan R, Dharumadurai D, Manogaran GP (2016) An Introduction to Actinobacteria. Marine Microbiology: Bioactive Compounds and Biotechnological Applications. Wiley publishers, New York, pp 1\u201319"},{"key":"8283_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-019-47406-y","volume":"9","author":"Y Nindita","year":"2019","unstructured":"Nindita Y, Cao Z, Fauzi AA, Teshima A, Misaki Y, Muslimin R (2019) The genome sequence of Streptomyces rochei 7434AN4, which carries a linear chromosome and three characteristic linear plasmids. Sci Rep 9:1\u20134. https:\/\/doi.org\/10.1038\/s41598-019-47406-y","journal-title":"Sci Rep"},{"key":"8283_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2164-13-337","volume":"13","author":"H Wu","year":"2012","unstructured":"Wu H, Qu S, Lu C, Zheng H, Zhou X, Bai L, Deng Z (2012) Genomic and transcriptomic insights into the thermo-regulated biosynthesis of validamycin in Streptomyces hygroscopicus 5008. BMC Genom 13:1\u20134. https:\/\/doi.org\/10.1186\/1471-2164-13-337","journal-title":"BMC Genom"},{"key":"8283_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jbiotec.2015.12.010","volume":"219","author":"SH Lee","year":"2016","unstructured":"Lee SH, Choe H, Bae KS, Park DS, Nasir A, Kim KM (2016) Complete genome of Streptomyces hygroscopicus subsp. limoneus KCTC 1717 (= KCCM 11405), a soil bacterium producing validamycin and diverse secondary metabolites. J Biotechnol 219:1\u20132. https:\/\/doi.org\/10.1016\/j.jbiotec.2015.12.010","journal-title":"J Biotechnol"},{"key":"8283_CR43","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1046\/j.1365-2958.1998.00652.x","volume":"27","author":"JN Volff","year":"1998","unstructured":"Volff JN, Altenbuchner J (1998) Genetic instability of the Streptomyces chromosome. Mol Microbiol 27:239\u2013246. https:\/\/doi.org\/10.1046\/j.1365-2958.1998.00652.x","journal-title":"Mol Microbiol"},{"key":"8283_CR44","doi-asserted-by":"publisher","first-page":"124","DOI":"10.3390\/microorganisms7050124","volume":"7","author":"C Risdian","year":"2019","unstructured":"Risdian C, Mozefm T, Wink J (2019) Biosynthesis of polyketides in Streptomyces. Microorganisms 7:124. https:\/\/doi.org\/10.3390\/microorganisms7050124","journal-title":"Microorganisms"},{"key":"8283_CR45","doi-asserted-by":"publisher","first-page":"7839","DOI":"10.1073\/pnas.92.17.7839","volume":"92","author":"T Schwecke","year":"1995","unstructured":"Schwecke T, Apariciom JF, Moln\u00e1r I, K\u00f6nig A, Khaw LE, Haydock SF, Caffrey P, Cortes J, Lester JB (1995) The biosynthetic gene cluster for the polyketide immunosuppressant rapamycin. Proc Natl Acad Sci USA 92:7839\u201343","journal-title":"Proc Natl Acad Sci USA"},{"key":"8283_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0378-1119(95)00799-7","volume":"169","author":"I Moln\u00e1r","year":"1996","unstructured":"Moln\u00e1r I, Aparicio JF, Haydock S, Khaw LE, Schwecke T, K\u00f6nig A, Staunton J, Leadlay PF (1996) Organisation of the biosynthetic gene cluster for rapamycin in Streptomyces hygroscopicus: analysis of genes flanking the polyketide synthase. Gene 169:1\u20137. https:\/\/doi.org\/10.1016\/0378-1119(95)00799-7","journal-title":"Gene"},{"key":"8283_CR47","doi-asserted-by":"publisher","first-page":"3838","DOI":"10.1021\/ja0587603","volume":"128","author":"GJ Gatto","year":"2006","unstructured":"Gatto GJ, Boyne MT, Kelleher NL, Walsh CT (2006) Biosynthesis of pipecolic acid by RapL, a lysine cyclodeaminase encoded in the rapamycin gene cluster. J Am Chem Soc 128:3838\u20133847. https:\/\/doi.org\/10.1021\/ja0587603","journal-title":"J Am Chem Soc"},{"key":"8283_CR48","doi-asserted-by":"publisher","first-page":"4756","DOI":"10.1128\/JB.00129-07","volume":"189","author":"E Ku\u0161\u010der","year":"2007","unstructured":"Ku\u0161\u010der E, Coates N, Challis I, Gregory M, Wilkinson B, Sheridan R, Petkovic H (2007) Roles of rapH and rapG in positive regulation of rapamycin biosynthesis in Streptomyces hygroscopicus. J Bacteriol 189:4756\u20134763. https:\/\/doi.org\/10.1128\/JB.00129-07","journal-title":"J Bacteriol"},{"key":"8283_CR49","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1021\/np50073a015","volume":"54","author":"NL Patva","year":"1991","unstructured":"Patva NL, Demain AL, Roberts MF (1991) Incorporation of acetate, propionate, and methionine into rapamycin by streptomyces hygroscopicus. J Nat Prod 54:167\u2013177","journal-title":"J Nat Prod"},{"key":"8283_CR50","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/sj.jim.2900527","volume":"20","author":"DJ Wilson","year":"1998","unstructured":"Wilson DJ, Patton S, Florova G, Hale V, Reynolds KA (1998) The shikimic acid pathway and polyketide biosynthesis. J Ind Microbiol Biotechnol 20:299\u2013303. https:\/\/doi.org\/10.1038\/sj.jim.2900527","journal-title":"J Ind Microbiol Biotechnol"},{"key":"8283_CR51","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1146\/annurev.arplant.50.1.473","volume":"50","author":"KM Herrman","year":"1999","unstructured":"Herrman KM, Weaver LM (1999) The shikimate pathway. Annu Rev Plant Physiol Plant Mol Biol 50:473\u2013503","journal-title":"Annu Rev Plant Physiol Plant Mol Biol"},{"key":"8283_CR52","doi-asserted-by":"publisher","first-page":"4776","DOI":"10.1073\/pnas.1015773108","volume":"108","author":"JN Andexer","year":"2011","unstructured":"Andexer JN, Kendrew SG, Nur-e-Alam M, Lazos O, Foster TA, Zimmermann AS, Warneck TD, Suthar D, Coates NJ, Koehn FE, Skotnicki J (2011) Biosynthesis of the immunosuppressants FK506, FK520, and rapamycin involves a previously undescribed family of enzymes acting on chorismate. Proc Natl Acad Sci USA 108:4776\u20134781. https:\/\/doi.org\/10.1073\/pnas.1015773108","journal-title":"Proc Natl Acad Sci USA"},{"key":"8283_CR53","doi-asserted-by":"publisher","first-page":"2551","DOI":"10.1002\/anie.200453764","volume":"43","author":"MA Gregory","year":"2004","unstructured":"Gregory MA, Gaisser S, Lill RE, Hong H, Sheridan RM, Wilkinson B (2004) Isolation and characterization of pre-rapamycin, the first macrocyclic intermediate in the biosynthesis of the immunosuppressant rapamycin by S. hygroscopicus. Angew Chemie - Int Ed 43:2551\u20132553. https:\/\/doi.org\/10.1002\/anie.200453764","journal-title":"Angew Chemie - Int Ed"},{"key":"8283_CR54","doi-asserted-by":"publisher","first-page":"6092","DOI":"10.3390\/molecules16076092","volume":"16","author":"DH Kwan","year":"2011","unstructured":"Kwan DH, Schulz F (2011) The stereochemistry of complex polyketide biosynthesis by modular polyketide synthases. Molecules 16:6092\u2013115. https:\/\/doi.org\/10.3390\/molecules16076092","journal-title":"Molecules"},{"key":"8283_CR55","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1002\/1521-3773(20010216)40:4<777::AID-ANIE7770>3.0.CO;2-9","volume":"40","author":"PA Lowden","year":"2001","unstructured":"Lowden PA, Wilkinson, B\u00f6hm GA, Handa S, Floss HG, Leadlay PF, Staunton J (2001) Origin and true nature of the starter unit for the rapamycin polyketide synthase. Angew Chemie. - Int Ed 40:799\u2013801","journal-title":"- Int Ed"},{"key":"8283_CR56","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1111\/j.1432-1033.1997.00526.x","volume":"247","author":"A K\u00f6nig","year":"1997","unstructured":"K\u00f6nig A, Schwecke T, Moln\u00e1r I, B\u00f6hm GA, Lowden PA, Staunton J, Leadlay PF (1997) The pipecolate-incorporating enzyme for the biosynthesis of the immunosuppressant rapamycin - nucleotide sequence analysis, disruption and heterologous expression of rapP from Streptomyces hygroscopicus. Eur J Biochem 247:526\u2013534. https:\/\/doi.org\/10.1111\/j.1432-1033.1997.00526.x","journal-title":"Eur J Biochem"},{"key":"8283_CR57","first-page":"4375","volume":"58","author":"JN Sarkaria","year":"1998","unstructured":"Sarkaria JN, Tibbetts RS, Busby EC, Kennedy AP, Hill DE, Abraham RT (1998) Inhibition of phosphoinositide 3-kinase related kinases by the radiosensitizing agent wortmannin. Cancer Res 58:4375\u20134382","journal-title":"Cancer Res"},{"key":"8283_CR58","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1016\/j.cub.2004.06.054","volume":"14","author":"DD Sarbassov","year":"2004","unstructured":"Sarbassov DD, Ali SM, Kim DH, Guertin DA, Latek RR, Erdjument-Bromage H, Tempst P, Sabatini DM (2004) Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol 14:1296\u20131302","journal-title":"Curr Biol"},{"key":"8283_CR59","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1186\/1748-717X-1-11","volume":"3","author":"LQ Chow","year":"2007","unstructured":"Chow LQ, Chen C, Raben D (2007) EGFR inhibitors and radiation in HNSCC. Curr Cancer Ther Rev 3:255\u2013266. https:\/\/doi.org\/10.1186\/1748-717X-1-11","journal-title":"Curr Cancer Ther Rev"},{"key":"8283_CR60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13578-020-00396-1","volume":"10","author":"Z Zou","year":"2020","unstructured":"Zou Z, Tao T, Li H, Zhu X (2020) MTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges. Cell Biosci 10:1\u20131","journal-title":"Cell Biosci"},{"key":"8283_CR61","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1126\/science.1106148","volume":"307","author":"DD Sarbassov","year":"2005","unstructured":"Sarbassov DD, Guertin D, Ali SM, Sabatini DM (2005) Phosphorylation and regulation of Akt\/PKB by the rictor-mTOR complex. Science 307:1098\u20131101. https:\/\/doi.org\/10.1126\/science.1106148","journal-title":"Science"},{"key":"8283_CR62","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/nrm3025","volume":"12","author":"R Zoncu","year":"2011","unstructured":"Zoncu R, Efeyan A, Sabatini DM (2011) MTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 12:21\u201335. https:\/\/doi.org\/10.1038\/nrm3025","journal-title":"Nat Rev Mol Cell Biol"},{"key":"8283_CR63","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/j.cell.2017.02.004","volume":"168","author":"RA Saxton","year":"2017","unstructured":"Saxton RA, Sabatini DM (2017) mTOR signaling in growth, metabolism, and disease. Cell 168:960\u2013976. https:\/\/doi.org\/10.1016\/j.cell.2017.02.004","journal-title":"Cell"},{"key":"8283_CR64","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1126\/science.273.5272.239","volume":"273","author":"J Choi","year":"1996","unstructured":"Choi J, Chen J, Schreiber SL, Clardy J (1996) Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP. Science 273:239\u2013242. https:\/\/doi.org\/10.1126\/science.273.5272.239","journal-title":"Science"},{"key":"8283_CR65","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M113.531392","volume-title":"The role of diacylglycerol kinase Zeta in Mechanotransduction: a positive Regulator of skeletal muscle Mass","author":"JS You","year":"2016","unstructured":"You JS (2016) The role of diacylglycerol kinase Zeta in Mechanotransduction: a positive Regulator of skeletal muscle Mass. The University of Wisconsin-Madison, Madison. https:\/\/doi.org\/10.1074\/jbc.M113.531392"},{"key":"8283_CR66","doi-asserted-by":"publisher","first-page":"10294","DOI":"10.1021\/bi060976+","volume":"45","author":"M Leone","year":"2006","unstructured":"Leone M, Crowell KJ, Chen J, Jung D, Chiang GG, Sareth S, Abraham RT, Pellecchia M (2006) The FRB domain of mTOR: NMR solution structure and inhibitor design. Biochemistry 45:10294\u201310302. https:\/\/doi.org\/10.1021\/bi060976+","journal-title":"Biochemistry"},{"key":"8283_CR67","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1101\/gad.12.4.502","volume":"12","author":"AC Gingras","year":"1998","unstructured":"Gingras AC, Kennedy SG, O\u2019Leary MA, Sonenberg N, Hay N (1998) 4E-BP1, a repressor of mRNA translation, is phosphorylated and inactivated by the akt(PKB) signaling pathway. Genes Dev 12:502\u2013513. https:\/\/doi.org\/10.1101\/gad.12.4.502","journal-title":"Genes Dev"},{"key":"8283_CR68","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1126\/science.277.5322.99","volume":"277","author":"GJ Brunn","year":"1997","unstructured":"Brunn GJ, Hudson CC, Sekulic A, Williams JM, Hosoi H, Houghton PJ, Lawrence JC Jr, Abraham RT (1997) Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin. Science 277:99\u2013101. https:\/\/doi.org\/10.1126\/science.277.5322.99","journal-title":"Science"},{"key":"8283_CR69","doi-asserted-by":"publisher","first-page":"4525","DOI":"10.1128\/mcb.19.6.4525","volume":"19","author":"A Dufner","year":"1999","unstructured":"Dufner A, Andjelkovic M, Burgering BMT, Hemmings BA, Thomas G (1999) Protein kinase B localization and activation differentially affect S6 kinase 1 activity and eukaryotic translation initiation factor 4E-Binding protein 1 phosphorylation. Mol Cell Biol 19:4525\u20134534. https:\/\/doi.org\/10.1128\/mcb.19.6.4525","journal-title":"Mol Cell Biol"},{"key":"8283_CR70","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1093\/annonc\/mdi113","volume":"16","author":"S Vignot","year":"2005","unstructured":"Vignot S, Faivre S, Aguirre D, Raymond E (2005) mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol 16:525\u2013537. https:\/\/doi.org\/10.1093\/annonc\/mdi113","journal-title":"Ann Oncol"},{"key":"8283_CR71","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.canlet.2015.01.043","volume":"360","author":"A Chatterjee","year":"2015","unstructured":"Chatterjee A, Mukhopadhyay S, Tung K, Patel D, Foster DA (2015) Rapamycin-induced G1 cell cycle arrest employs both TGF-\u03b2 and rb pathways. Cancer Lett 360:134\u2013140. https:\/\/doi.org\/10.1016\/j.canlet.2015.01.043","journal-title":"Cancer Lett"},{"key":"8283_CR72","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-18930-2_15","author":"DH Kim","year":"2003","unstructured":"Kim DH, Sabatini DM (2003) Raptor and mTOR: subunits of a nutrient-sensitive complex. Curr Top Microbiol Immunol 259 \u2013 70. https:\/\/doi.org\/10.1007\/978-3-642-18930-2_15","journal-title":"Curr Top Microbiol Immunol 259 \u2013 70"},{"key":"8283_CR73","first-page":"880","volume":"6","author":"L Hu","year":"2000","unstructured":"Hu L, Zaloudek C, Mills GB, Gray J, Jaffe RB (2000) In-vivo and in-vitro ovarian carcinoma growth inhibition by a phosphatidylinositol 3-kinase inhibitor (LY294002). Clin Cancer Res 6:880\u20136","journal-title":"Clin Cancer Res"},{"key":"8283_CR74","first-page":"5758","volume":"56","author":"T Seufferlein","year":"1996","unstructured":"Seufferlein T, Rozengurt E (1996) Galanin, neurotensin, and phorbol esters rapidly stimulate activation of mitogen-activated protein kinase in small cell lung cancer cells. Cancer Res 56:5758\u20135764","journal-title":"Cancer Res"},{"key":"8283_CR75","doi-asserted-by":"publisher","first-page":"6680","DOI":"10.1038\/sj.onc.1204091","volume":"19","author":"M Hidalgo","year":"2000","unstructured":"Hidalgo M, Rowinsky EK (2000) The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene 19:6680\u20136686. https:\/\/doi.org\/10.1038\/sj.onc.1204091","journal-title":"Oncogene"},{"key":"8283_CR76","first-page":"561","volume":"91","author":"S Kawamata","year":"1998","unstructured":"Kawamata S, Sakaida H, Hori T, Maeda M, Uchiyama T (1998) The Upregulation of p27Kip1 by Rapamycin results in G1 arrest in exponentially growing T-Cell lines. Blood Am J Hematol 91:561\u2013569","journal-title":"Blood Am J Hematol"},{"key":"8283_CR77","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1006\/cimm.1994.1193","volume":"91","author":"KM Aagaard-Tillery","year":"1994","unstructured":"Aagaard-Tillery KM, Jelinek DF (1994) Inhibition of human B lymphocyte cell cycle progression and differentiation by rapamycin. Cell Immunol 91:561\u2013569. https:\/\/doi.org\/10.1006\/cimm.1994.1193","journal-title":"Cell Immunol"},{"key":"8283_CR78","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1006\/bcmd.2001.0420","volume":"27","author":"J Gonzalez","year":"2001","unstructured":"Gonzalez J, Harris T, Childs G, Prystowsky MB (2001) Rapamycin blocks IL-2-driven T cell cycle progression while preserving T cell survival. Blood Cells Mol Dis 27:572\u2013585. https:\/\/doi.org\/10.1006\/bcmd.2001.0420","journal-title":"Blood Cells Mol Dis"},{"key":"8283_CR79","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1128\/mcb.15.1.326","volume":"15","author":"M Monfar","year":"1995","unstructured":"Monfar M, Lemon KP, Grammer TC, Cheatham L, Chung J, Vlahos CJ, Blenis J (1995) Activation of pp70\/85 S6 kinases in interleukin-2-responsive lymphoid cells is mediated by phosphatidylinositol 3-kinase and inhibited by cyclic AMP. Mol Cell Biol 15:326\u2013337. https:\/\/doi.org\/10.1128\/mcb.15.1.326","journal-title":"Mol Cell Biol"},{"key":"8283_CR80","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1146\/annurev.iy.10.040192.002511","volume":"10","author":"NH Sigal","year":"1992","unstructured":"Sigal NH, Dumont FJ (1992) Cyclosporin A, FK-506, and rapamycin: pharmacologic probes of lymphocyte signal transduction. Annu Rev Immunol 10:519\u2013560. https:\/\/doi.org\/10.1146\/annurev.iy.10.040192.002511","journal-title":"Annu Rev Immunol"},{"key":"8283_CR81","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1126\/science.1715094","volume":"253","author":"J Heitman","year":"1991","unstructured":"Heitman J, Movva NR, Hall MN (1991) Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science 253:905\u2013909. https:\/\/doi.org\/10.1126\/science.1715094","journal-title":"Science"},{"key":"8283_CR82","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1126\/science.1709302","volume":"252","author":"GD Van Duyne","year":"1991","unstructured":"Van Duyne GD, Standaert RF, Karplus PA, Schreiber SL, Clardy J (1991) Atomic structure of FKBP-FK506, an immunophilin-immunosuppressant complex. Science 252:839\u2013842. https:\/\/doi.org\/10.1126\/science.1709302","journal-title":"Science"},{"key":"8283_CR83","doi-asserted-by":"publisher","DOI":"10.5402\/2011\/536484","author":"EA Rahal","year":"2011","unstructured":"Rahal EA, Chakhtoura M, Abu Dargham R, Khauli RB, Medawar W, Abdelnoor AM (2011) Advantages of sirolimus in a calcineurin-inhibitor minimization protocol for the immunosuppressive management of kidney allograft recipients. ISRN Immunol. https:\/\/doi.org\/10.5402\/2011\/536484","journal-title":"ISRN Immunol"},{"key":"8283_CR84","doi-asserted-by":"publisher","first-page":"113544","DOI":"10.1126\/science.1709302","volume":"416","author":"S Vellanki","year":"2020","unstructured":"Vellanki S, Garcia AE, Lee SC (2020) Interactions of FK506 and rapamycin with FK506 binding protein 12 in opportunistic human fungal pathogens. Front mol biosci 416:113544. https:\/\/doi.org\/10.1126\/science.1709302","journal-title":"Front mol biosci"},{"key":"8283_CR85","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/0167-5699(92)90111-J","volume":"13","author":"SL Schreiber","year":"1992","unstructured":"Schreiber SL, Crabtree GR (1992) The mechanism of action of cyclosporin A and FK506. Immunol Today 13:136\u201342","journal-title":"Immunol Today"},{"key":"8283_CR86","doi-asserted-by":"publisher","first-page":"5767","DOI":"10.1128\/IAI.73.9.5767-5774.2005","volume":"73","author":"JR Blankenship","year":"2005","unstructured":"Blankenship JR, Heitman J (2005) Calcineurin is required for Candida albicans to survive calcium stress in serum. Infect Immun 73:5767\u20135774. https:\/\/doi.org\/10.1128\/IAI.73.9.5767-5774.2005","journal-title":"Infect Immun"},{"key":"8283_CR87","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1016\/j.transproceed.2005.02.101","volume":"37","author":"B Forgacs","year":"2005","unstructured":"Forgacs B, Merhav HJ, Lappin J, Mieles L (2005) Successful conversion to rapamycin for calcineurin inhibitor-related neurotoxicity following liver transplantation. Transpl Proc 37:912\u20131914. https:\/\/doi.org\/10.1016\/j.transproceed.2005.02.101","journal-title":"Transpl Proc"},{"key":"8283_CR88","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1046\/j.1523-1755.2001.00460.x","volume":"59","author":"R Saunders","year":"2001","unstructured":"Saunders R, Metcalfe MS, Nicholson ML (2001) Rapamycin in transplantation: a review of the evidence. Kidney Int 59:3\u201316. https:\/\/doi.org\/10.1046\/j.1523-1755.2001.00460.x","journal-title":"Kidney Int"},{"key":"8283_CR89","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1111\/ajt.13151","volume":"15","author":"D Fantus","year":"2015","unstructured":"Fantus D, Thomson AW (2015) Evolving perspectives of mTOR complexes in immunity and transplantation. Am J Transplant 15:891\u2013902. https:\/\/doi.org\/10.1111\/ajt.13151","journal-title":"Am J Transplant"},{"key":"8283_CR90","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1161\/01.cir.100.1.67","volume":"100","author":"RS Poston","year":"1999","unstructured":"Poston RS, Billingham M, Hoyt EG, Pollard J, Shorthouse R, Morris RE, Robbins RC (1999) Rapamycin reverses chronic graft vascular disease in a novel cardiac allograft model. Circulation 100:67\u201374. https:\/\/doi.org\/10.1161\/01.cir.100.1.67","journal-title":"Circulation"},{"key":"8283_CR91","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1053\/jlts.2001.24645","volume":"7","author":"P Neuhaus","year":"2001","unstructured":"Neuhaus P, Klupp J, Langrehr JM (2001) mTOR inhibitors: an overview. Liver Transpl 7:473\u2013484. https:\/\/doi.org\/10.1053\/jlts.2001.24645","journal-title":"Liver Transpl"},{"key":"8283_CR92","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0024-3205(95)02233-3","volume":"58","author":"FJ Dumont","year":"1995","unstructured":"Dumont FJ, Su Q (1995) Mechanism of action of the immunosuppressant rapamycin. Life Sci 58:373\u2013395. https:\/\/doi.org\/10.1016\/0024-3205(95)02233-3","journal-title":"Life Sci"},{"key":"8283_CR93","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1097\/00007890-199205000-00019","volume":"53","author":"H Luo","year":"1992","unstructured":"Luo H, Chen H, Daloze P, Chang JY, St-Louis GWJ (1992) Inhibition of in-vitro immunoglobulin production by rapamycin. Transplantation 53:1071\u20131076. https:\/\/doi.org\/10.1097\/00007890-199205000-00019","journal-title":"Transplantation"},{"key":"8283_CR94","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1111\/j.1399-3046.2011.01575.x","volume":"15","author":"B Kasap","year":"2011","unstructured":"Kasap B (2011) Sirolimus in pediatric renal transplantation. Pediatr Transpl 15:673\u2013685. https:\/\/doi.org\/10.1111\/j.1399-3046.2011.01575.x","journal-title":"Pediatr Transpl"},{"key":"8283_CR95","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1097\/00007890-199501000-00005","volume":"59","author":"D Granger","year":"1995","unstructured":"Granger D, Cromwell JW, Chen SC, Goswitz JJ, Morrow DT, Beierle FA, Suren, Sehgal Daniel M, Canafax, Arthur J, Matas AL (1995) Prolongation of renal allograft survival in a large animal model by oral rapamycin monotherapy. Transplantation 59:183\u2013186","journal-title":"Transplantation"},{"key":"8283_CR96","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1111\/j.1749-6632.1993.tb35858.x","volume":"56","author":"PS Almond","year":"1993","unstructured":"Almond PS, Moss A, Nakhleh RE, Melin M, Chen S, Salazar A, Ken Shirabe, Arthur J, Matas (1993) Rapamycin: immunosuppression, hyporesponsiveness, and side effects in a porcine renal allograft model. Transplantation 56:275\u2013281. https:\/\/doi.org\/10.1111\/j.1749-6632.1993.tb35858.x","journal-title":"Transplantation"},{"key":"8283_CR97","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1159\/000079808","volume":"27","author":"L Renders","year":"2004","unstructured":"Renders L, Steinbach R, Valerius T, Sch\u00f6cklmann HO, Kunzendorf U (2004) Low-dose sirolimus in combination with mycophenolate mofetil improves kidney graft function late after renal transplantation and suggests pharmacokinetic interaction of both immunosuppressive drugs. Kidney Blood Press Res 27:181\u2013185. https:\/\/doi.org\/10.1159\/000079808","journal-title":"Kidney Blood Press Res"},{"key":"8283_CR98","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1161\/01.CIR.0000070421.38604.2B","volume":"108","author":"D Mancini","year":"2003","unstructured":"Mancini D, Pinney S, Burkhoff D, LaManca J, Itescu S, Burke E, Edwards N, Oz M, Marks AR (2003) Use of rapamycin slows progression of cardiac transplantation vasculopathy. Circulation 108:48\u201353. https:\/\/doi.org\/10.1161\/01.CIR.0000070421.38604.2B","journal-title":"Circulation"},{"key":"8283_CR99","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1016\/j.healun.2005.08.015","volume":"24","author":"SS Kushwaha","year":"2005","unstructured":"Kushwaha SS, Khalpey Z, Frantz RP, Rodeheffer RJ, Clavell AL, Daly RC, Christopher G, McGregor., Brooks S, Edwards, (2005) Sirolimus in cardiac transplantation: Use as a primary immunosuppressant in calcineurin inhibitor-induced nephrotoxicity. J Heart Lung Transplant 24:2129\u201336","journal-title":"J Heart Lung Transplant"},{"key":"8283_CR100","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1097\/01.tp.0000177644.45192.a3","volume":"81","author":"R Bestetti","year":"2006","unstructured":"Bestetti R, Theodoropoulos TAD, Burdmann EA, Abbud FM, Cordeiro JA, Villafanha D (2006) Switch from calcineurin inhibitors to sirolimus-induced renal recovery in heart transplant recipients in the midterm follow-up. Transplantation 81:692\u2013696. https:\/\/doi.org\/10.1097\/01.tp.0000177644.45192.a3","journal-title":"Transplantation"},{"key":"8283_CR101","doi-asserted-by":"publisher","first-page":"3835","DOI":"10.1016\/j.transproceed.2009.06.236","volume":"41","author":"JF Delgado","year":"2009","unstructured":"Delgado JF, Crespo MG, Manito N, Camprecios M, R\u00e1bago G, Lage E, Ariz\u00f3n JM, Roig E, Lage E (2009) Usefulness of sirolimus as rescue therapy in heart transplant recipients with renal failure: analysis of the spanish multicenter observational study (RAPACOR). Transpl Proc 41:3835\u20133837. https:\/\/doi.org\/10.1016\/j.transproceed.2009.06.236","journal-title":"Transpl Proc"},{"key":"8283_CR102","doi-asserted-by":"publisher","unstructured":"Ussetti P, Laporta R, De Pablo A, Carreno C, Segovia J, Pulp\u00f3n L (2003) Rapamycin in lung transplantation: preliminary results. Transpl Proc 35(5):1974\u20131977. https:\/\/doi.org\/10.1016\/s0041-1345(03)00688-2","DOI":"10.1016\/s0041-1345(03)00688-2"},{"key":"8283_CR103","doi-asserted-by":"publisher","first-page":"2558","DOI":"10.1097\/TP.0000000000001432","volume":"100","author":"NM Fine","year":"2016","unstructured":"Fine NM, Kushwaha SS (2016) Recent advances in mammalian target of rapamycin inhibitor use in Heart and Lung Transplantation. Transplantation 100:2558\u20132568. https:\/\/doi.org\/10.1097\/TP.0000000000001432","journal-title":"Transplantation"},{"key":"8283_CR104","doi-asserted-by":"publisher","first-page":"e36589","DOI":"10.1371\/journal.pone.0036589","volume":"7","author":"Z Zhang","year":"2012","unstructured":"Zhang Z, Wu X, Duan J, Hinrichs D, Wegmann K, Zhang GL, Hall M, Rosenbaum JT (2012) Low dose rapamycin exacerbates autoimmune experimental uveitis. PLoS One 7:e36589. https:\/\/doi.org\/10.1371\/journal.pone.0036589","journal-title":"PLoS One"},{"key":"8283_CR105","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2021-000617","author":"L Peng","year":"2020","unstructured":"Peng L, Wu C, Hong R, Sun Y, Qian J, Zhao J, Wang Q, Tian X, Wang Y, Li M, Zeng X (2020) Clinical efficacy and safety of sirolimus in systemic lupus erythematosus: a real-world study and meta-analysis. Ther Adv Musculoskelet Dis. https:\/\/doi.org\/10.1136\/lupus-2021-000617","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"274","key":"8283_CR106","doi-asserted-by":"publisher","first-page":"274ra18","DOI":"10.1126\/scitranslmed.aaa0835","volume":"7","author":"Y Yin","year":"2015","unstructured":"Yin Y, Choi SC, Xu Z, Perry DJ, Seay H, Croker BP et al (2015) Normalization of CD4 + T cell metabolism reverses lupus. Sci Transl Med 7(274):274ra18. https:\/\/doi.org\/10.1126\/scitranslmed.aaa0835","journal-title":"Sci Transl Med"},{"key":"8283_CR107","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1097\/00002281-200305000-00008","volume":"15","author":"DF Mayer","year":"2003","unstructured":"Mayer DF, Kushwaha SS (2003) Transplant immunosuppressant agents and their role in autoimmune rheumatic diseases. Curr Opin Rheumatol 15:219\u2013225. https:\/\/doi.org\/10.1097\/00002281-200305000-00008","journal-title":"Curr Opin Rheumatol"},{"key":"8283_CR108","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1136\/ard.2010.134684","volume":"69","author":"IB McInnes","year":"2010","unstructured":"McInnes IB, O\u2019Dell JR (2010) State-of-the-art: rheumatoid arthritis. Ann Rheum Dis 69:1898\u2013906","journal-title":"Ann Rheum Dis"},{"key":"8283_CR109","doi-asserted-by":"publisher","first-page":"5257","DOI":"10.3892\/mmr.2017.7285","volume":"16","author":"P Shao","year":"2017","unstructured":"Shao P, Ma L, Ren Y, Liu H (2017) Modulation of the immune response in rheumatoid arthritis with strategically released rapamycin. Mol Med Rep 16:5257\u20135262. https:\/\/doi.org\/10.3892\/mmr.2017.7285","journal-title":"Mol Med Rep"},{"key":"8283_CR110","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1002\/art.40770","volume":"71","author":"MN van Tok","year":"2019","unstructured":"van Tok MN, van Duivenvoorde LM, Kramer I, Ingold P, Pfister S, Roth L, Blijdorp IC, van de Sande MG, Taurog JD, Kolbinger F (2019) Baeten Interleukin-17A Inhibition diminishes inflammation and new bone formation in experimental spondyloarthritis. Arthritis Rheumatol 71:612\u2013625. https:\/\/doi.org\/10.1002\/art.40770","journal-title":"Arthritis Rheumatol"},{"key":"8283_CR111","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02344","author":"S Chen","year":"2020","unstructured":"Chen S, van Tok MN, Knaup VL, Kraal L, Pots D, Bartels L, Gravallese EM, Taurog JD, van de Sande M, van Duivenvoorde LM, Baeten DL (2020) mTOR blockade by rapamycin in spondyloarthritis: impact on inflammation and new bone formation in-vitro and in-vivo. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2019.02344","journal-title":"Front Immunol"},{"key":"8283_CR112","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1111\/j.1432-2277.2004.00070.x","volume":"18","author":"B Foroncewicz","year":"2005","unstructured":"Foroncewicz B, Mucha K, Pa\u0327czek L, Chmura A, Rowi\u0144ski W, (2005) Efficacy of rapamycin in patient with juvenile rheumatoid arthritis. Transpl Int 18:366\u20138","journal-title":"Transpl Int"},{"key":"8283_CR113","doi-asserted-by":"publisher","first-page":"73","DOI":"10.14712\/18059694.2016.63","volume":"53","author":"K Kond\u011blkov\u00e1","year":"2010","unstructured":"Kond\u011blkov\u00e1 K, Vokurkov\u00e1 D, Krejsek J, Borsk\u00e1 L, Fiala Z, Ctirad A (2010) Regulatory T cells (TREG) and their roles in immune system with respect to immunopathological disorders. Acta Med 53:73\u201377. https:\/\/doi.org\/10.14712\/18059694.2016.63","journal-title":"Acta Med"},{"key":"8283_CR114","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/cmi.2015.10","volume":"12","author":"Z Li","year":"2015","unstructured":"Li Z, Li D, Tsun A, Li B (2015) FOXP3 + regulatory T cells and their functional regulation. Mol Immunol 12:558\u2013565. https:\/\/doi.org\/10.1038\/cmi.2015.10","journal-title":"Mol Immunol"},{"key":"8283_CR115","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.jaut.2012.12.004","volume":"41","author":"H Katoh","year":"2013","unstructured":"Katoh H, Zheng P, Liu Y (2013) FOXP3: genetic and epigenetic implications for autoimmunity. J Autoimmun 41:72\u20138. https:\/\/doi.org\/10.1016\/j.jaut.2012.12.004","journal-title":"J Autoimmun"},{"key":"8283_CR116","doi-asserted-by":"publisher","first-page":"S365","DOI":"10.1016\/j.bbmt.2016.12.314","volume":"23","author":"G Ehx","year":"2017","unstructured":"Ehx G, Hannon M, Dubois S, Daulne C, Drion P, Beguin Y, Humblet-Baron S (2017) Immunomodulatory effects of rapamycin in xenogeneic graft versus host disease. Biol Blood Marrow Transplant 23:S365\u2013S366. https:\/\/doi.org\/10.1016\/j.bbmt.2016.12.314","journal-title":"Biol Blood Marrow Transplant"},{"key":"8283_CR117","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1223","author":"Y Lu","year":"2014","unstructured":"Lu Y, Wang J, Gu J, Lu H, Li X, Qian X, Liu X, Wang X, Zhang F, Lu L (2014) Rapamycin regulates iTreg function through CD39 and Runx1 pathways. J Immunol Res. https:\/\/doi.org\/10.1002\/cti2.1223","journal-title":"J Immunol Res"},{"issue":"1","key":"8283_CR118","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.transproceed.2008.10.079","volume":"41","author":"AK Singh","year":"2009","unstructured":"Singh AK, Horvath KA, Mohiuddin MM (2009) Rapamycin promotes the enrichment of CD4 + CD25hiFoxP3 + T regulatory cells from na\u00efve CD4 + T cells of baboon that suppress antiporcine xenogenic response in-vitro. Transpl Proc 41(1):418\u2013421. https:\/\/doi.org\/10.1016\/j.transproceed.2008.10.079","journal-title":"Transpl Proc"},{"issue":"1","key":"8283_CR119","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.critrevonc.2004.09.009","volume":"56","author":"BK Law","year":"2015","unstructured":"Law BK (2015) Rapamycin: an anti-cancer immunosuppressant? Crit Rev Oncol Hematol 56(1):47\u201360","journal-title":"Crit Rev Oncol Hematol"},{"key":"8283_CR120","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-019-0754-1","volume":"1","author":"K Hua Hui, Qingbin","year":"2019","unstructured":"Hua Hui, Qingbin K, Hongying Z, Jiao W, Ting L, Yangfu J (2019) Targeting mTOR for cancer therapy. J Hematol Oncol 1:1\u201319. https:\/\/doi.org\/10.1186\/s13045-019-0754-1","journal-title":"J Hematol Oncol"},{"issue":"22","key":"8283_CR121","doi-asserted-by":"publisher","first-page":"5520","DOI":"10.3390\/cancers14225520","volume":"14","author":"A Bouyahya","year":"2022","unstructured":"Bouyahya A, El Allam A, Aboulaghras S, Bakrim S, El Menyiy N, Alshahrani MM, Mubarak MS (2022) Targeting mTOR as a cancer therapy: recent advances in natural bioactive compounds and immunotherapy. Cancers 14(22):5520. https:\/\/doi.org\/10.3390\/cancers14225520","journal-title":"Cancers"},{"key":"8283_CR122","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1046\/j.1523-1755.2003.00805.x","volume":"63","author":"FL Luan","year":"2003","unstructured":"Luan FL, Ding R, Sharma VK, Chon WJ, Lagman M, Suthanthiran M (2003) Rapamycin is an effective inhibitor of human renal cancer metastasis. Kidney Int 63:917\u2013926. https:\/\/doi.org\/10.1046\/j.1523-1755.2003.00805.x","journal-title":"Kidney Int"},{"key":"8283_CR123","doi-asserted-by":"publisher","first-page":"6993","DOI":"10.1158\/1078-0432.CCR-04-0808","volume":"10","author":"S Stephan","year":"2004","unstructured":"Stephan S, Datta K, Wang E, Li J, Brekken RA, Parangi S, Thorpe PE, Mukhopadhyay D (2004) Effect of rapamycin alone and in combination with antiangiogenesis therapy in an orthotopic model of human pancreatic cancer. Clin Cancer Res 10:6993\u20137000. https:\/\/doi.org\/10.1158\/1078-0432.CCR-04-0808","journal-title":"Clin Cancer Res"},{"key":"8283_CR124","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1006\/jsre.2001.6145","volume":"97","author":"SA Shah","year":"2001","unstructured":"Shah SA, Potter MW, Ricciardi R, Perugini RA, Callery MP (2001) FRAP-p70s6K signaling is required for pancreatic cancer cell proliferation. J Surg Res 97:123\u2013130. https:\/\/doi.org\/10.1006\/jsre.2001.6145","journal-title":"J Surg Res"},{"key":"8283_CR125","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1006\/jsre.2001.6145","volume":"8","author":"M Guba","year":"2002","unstructured":"Guba M, Von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M, Bruns CJ, Zuelke C, Farkas S, Anthuber M, Jauch KW (2002) Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 8:128\u2013135. https:\/\/doi.org\/10.1006\/jsre.2001.6145","journal-title":"Nat Med"},{"key":"8283_CR126","doi-asserted-by":"publisher","first-page":"293","DOI":"10.2174\/138920311795659407","volume":"10","author":"DJ Boffa","year":"2004","unstructured":"Boffa DJ, Luan F, Thomas D, Yang H, Sharma VK, Lagman M, Suthanthiran M (2004) Rapamycin inhibits the growth and metastatic progression of non-small cell lung cancer. Clin Cancer Res 10:293\u2013300. https:\/\/doi.org\/10.2174\/138920311795659407","journal-title":"Clin Cancer Res"},{"key":"8283_CR127","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1113\/JP270923","volume":"594","author":"AK Uryga","year":"2016","unstructured":"Uryga AK, Bennett MR (2016) Ageing induced vascular smooth muscle cell senescence in atherosclerosis. J Physiol 594:2115\u20132124. https:\/\/doi.org\/10.1113\/JP270923","journal-title":"J Physiol"},{"key":"8283_CR128","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1080\/14756366.2021.1955873","volume":"36","author":"Z Chrienova","year":"2021","unstructured":"Chrienova Z, Nepovimova E, Kuca K (2021) The role of mTOR in age-related diseases. J Enzyme Inhib Med Chem 36:1679\u20131693. https:\/\/doi.org\/10.1080\/14756366.2021.1955873","journal-title":"J Enzyme Inhib Med Chem"},{"key":"8283_CR129","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.17196.1","author":"D Papadopoli","year":"2019","unstructured":"Papadopoli D, Boulay K, Kazak L, Pollak M, Mallette FA, Topisirovic I, Hulea L (2019) mTOR as a central regulator of lifespan and aging. F1000Research. https:\/\/doi.org\/10.12688\/f1000research.17196.1","journal-title":"F1000Research"},{"key":"8283_CR130","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.cub.2004.03.059","volume":"14","author":"P Kapahi","year":"2004","unstructured":"Kapahi P, Zid BM, Harper T, Koslover D, Sapin V, Benzer S (2004) Regulation of lifespan in Drosophila by modulation of genes in the TOR signaling pathway. Curr Biol 14:885\u2013890. https:\/\/doi.org\/10.1016\/j.cub.2004.03.059","journal-title":"Curr Biol"},{"issue":"2","key":"8283_CR131","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1159\/000484629","volume":"64","author":"T Weichhart","year":"2018","unstructured":"Weichhart T (2018) MTOR as regulator of lifespan, aging, and cellular senescence: a mini-review. Gerontology 64(2):127\u2013134. https:\/\/doi.org\/10.1159\/000484629","journal-title":"Gerontology"},{"key":"8283_CR132","doi-asserted-by":"publisher","first-page":"e8398","DOI":"10.1371\/journal.pone.0083988","volume":"9","author":"WC Fok","year":"2014","unstructured":"Fok WC, Chen Y, Bokov A, Zhang Y, Salmon AB, Diaz V, Javors M, Wood WH 3rd, Zhang Y, Becker KG, P\u00e9rez VI (2014) Mice fed rapamycin have an increase in lifespan associated with major changes in the liver transcriptome. PLoS One 9:e8398. https:\/\/doi.org\/10.1371\/journal.pone.0083988","journal-title":"PLoS One"},{"key":"8283_CR133","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1007\/s11357-020-00274-1","volume":"43","author":"R Selvarani","year":"2021","unstructured":"Selvarani R, Mohammed S, Richardson A (2021) Effect of rapamycin on aging and age-related diseases past and future. GeroScience 43:1135\u20131158. https:\/\/doi.org\/10.1007\/s11357-020-00274-1","journal-title":"GeroScience"},{"key":"8283_CR134","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1111\/acel.12194","volume":"13","author":"RA Miller","year":"2014","unstructured":"Miller RA, Harrison DE, Astle CM, Fernandez E, Flurkey K, Han M, Javors MA, Li X, Nadon NL, Nelson JF, Pletcher S (2014) Rapamycin-mediated lifespan increase in mice is dose and sex dependent and metabolically distinct from dietary restriction. Aging Cell 13:468\u2013477. https:\/\/doi.org\/10.1111\/acel.12194","journal-title":"Aging Cell"},{"key":"8283_CR135","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1093\/gerona\/glq178","volume":"66","author":"RA Miller","year":"2011","unstructured":"Miller RA, Harrison DE, Astle CM, Baur JA, Boyd AR, De Cabo R, Fernandez E, Flurkey K, Javors MA, Nelson JF, Orihuela CJ (2011) Rapamycin, but not resveratrol or simvastatin, extends life span of genetically heterogeneous mice. J Gerontol 66:191\u2013201. https:\/\/doi.org\/10.1093\/gerona\/glq178","journal-title":"J Gerontol"},{"key":"8283_CR136","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/nature08221","volume":"460","author":"DE Harrison","year":"2009","unstructured":"Harrison DE, Strong R, Sharp ZD, Nelson JF, Astle CM, Flurkey K, Nadon NL, Wilkinson JE, Frenkel K, Carter CS, Pahor M (2009) Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature 460:392\u2013395. https:\/\/doi.org\/10.1038\/nature08221","journal-title":"Nature"},{"key":"8283_CR137","doi-asserted-by":"publisher","first-page":"10271","DOI":"10.1073\/pnas.0601058103","volume":"103","author":"KN Dahl","year":"2006","unstructured":"Dahl KN, Scaffidi P, Islam MF, Yodh AG, Wilson KL, Misteli T (2006) Distinct structural and mechanical properties of the nuclear lamina in Hutchinson-Gilford progeria syndrome. Proc Natl Acad Sci 103:10271\u201310276. https:\/\/doi.org\/10.1073\/pnas.0601058103","journal-title":"Proc Natl Acad Sci"},{"key":"8283_CR138","doi-asserted-by":"publisher","first-page":"7190","DOI":"10.3390\/ijms22137190","volume":"22","author":"J Macicior","year":"2021","unstructured":"Macicior J, Marcos-Ramiro B, Ortega-Guti\u00e9rrez S (2021) Small-molecule therapeutic perspectives for the treatment of progeria. Int J Mol Sci 22:7190. https:\/\/doi.org\/10.3390\/ijms22137190","journal-title":"Int J Mol Sci"},{"key":"8283_CR139","first-page":"67","volume":"139","author":"JK Sinha","year":"2014","unstructured":"Sinha JK, Ghosh S, Raghunath M (2014) Progeria: a rare genetic premature ageing disorder. Indian J Med Sci 139:67","journal-title":"Indian J Med Sci"},{"key":"8283_CR140","doi-asserted-by":"publisher","first-page":"147","DOI":"10.4161\/auto.8.1.18331","volume":"8","author":"JJ Graziotto","year":"2012","unstructured":"Graziotto JJ, Cao K, Collins FS, Krainc D (2012) Rapamycin activates autophagy in Hutchinson-Gilford progeria syndrome: implications for normal aging and age-dependent neurodegenerative disorders. Autophagy 8:147\u2013151. https:\/\/doi.org\/10.4161\/auto.8.1.18331","journal-title":"Autophagy"},{"key":"8283_CR141","doi-asserted-by":"publisher","first-page":"89ra58","DOI":"10.1126\/scitranslmed.3002346","volume":"3","author":"K Cao","year":"2011","unstructured":"Cao K, Graziotto JJ, Blair CD, Mazzulli JR, Erdos MR, Krainc D, Collins FS (2011) Rapamycin reverses cellular phenotypes and enhances mutant protein clearance in Hutchinson-Gilford progeria syndrome cells. Sci Transl Med 3:89ra58. https:\/\/doi.org\/10.1126\/scitranslmed.3002346","journal-title":"Sci Transl Med"},{"key":"8283_CR142","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18632\/aging.103453","volume":"10","author":"J Aguado","year":"2019","unstructured":"Aguado J, Sola-Carvajal A, Cancila V, Rev\u00eachon G, Ong PF, Jones-Weinert CW, Wall\u00e9n Arzt E, Lattanzi G, Dreesen O, Tripodo C, Rossiello F (2019) Inhibition of DNA damage response at telomeres improves the detrimental phenotypes of Hutchinson\u2013Gilford Progeria Syndrome. Nat Commun 10:1\u20131. https:\/\/doi.org\/10.18632\/aging.103453","journal-title":"Nat Commun"},{"key":"8283_CR143","doi-asserted-by":"publisher","first-page":"2176","DOI":"10.3390\/cancers12061617","volume":"37","author":"K Watanabe","year":"2009","unstructured":"Watanabe K, Iwabuchi K, Sun J, Tsuji Y, Tani T, Tokunaga K, Date T, Hashimoto M, Yamaizumi M, Tateishi S (2009) RAD18 promotes DNA double-strand break repair during G1 phase through chromatin retention of 53BP1. Nucleic Acids Res 37:2176\u20132193. https:\/\/doi.org\/10.3390\/cancers12061617","journal-title":"Nucleic Acids Res"},{"key":"8283_CR144","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1093\/mutage\/15.4.289","volume":"15","author":"P Pfeiffer","year":"2000","unstructured":"Pfeiffer P, Goedecke W, Obe G (2000) Mechanisms of DNA double-strand break repair and their potential to induce chromosomal aberrations. Mutagenesis 15:289\u2013302. https:\/\/doi.org\/10.1093\/mutage\/15.4.289","journal-title":"Mutagenesis"},{"key":"8283_CR145","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1096\/fj.07-8598com","volume":"22","author":"Y Liu","year":"2008","unstructured":"Liu Y, Wang Y, Rusinol AE, Sinensky MS, Liu J, Shell SM, Zou Y (2008) Involvement of xeroderma pigmentosum group A (XPA) in progeria arising from defective maturation of prelamin A. FASEB J 22:603\u2013611. https:\/\/doi.org\/10.1096\/fj.07-8598com","journal-title":"FASEB J"},{"key":"8283_CR146","doi-asserted-by":"publisher","first-page":"28","DOI":"10.18632\/aging.100012","volume":"1","author":"PR Musich","year":"2009","unstructured":"Musich PR, Zou Y (2009) Genomic instability and DNA damage responses in progeria arising from defective maturation of prelamin. A Aging 1:28. https:\/\/doi.org\/10.18632\/aging.100012","journal-title":"A Aging"},{"key":"8283_CR147","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/nrn3068","volume":"12","author":"J Bov\u00e9","year":"2011","unstructured":"Bov\u00e9 J, Mart\u00ednez-Vicente M, Vila M (2011) Fighting neurodegeneration with rapamycin: mechanistic insights. Nat Rev Neurosci 12:437\u2013452. https:\/\/doi.org\/10.1038\/nrn3068","journal-title":"Nat Rev Neurosci"},{"key":"8283_CR148","doi-asserted-by":"publisher","DOI":"10.23937\/2643-4539\/1710010","author":"K Deeksha","year":"2010","unstructured":"Deeksha K, Abhishek N (2010) A review on Alzheimer disease. J Neurodegener Dis. https:\/\/doi.org\/10.23937\/2643-4539\/1710010","journal-title":"J Neurodegener Dis"},{"key":"8283_CR149","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1586\/ern.10.84","volume":"10","author":"PI Moreira","year":"2010","unstructured":"Moreira PI, Santos RX, Zhu X, Lee HG, Smith MA (2010) Casadesus G. Autophagy in Alzheimers disease. Expert Rev Neurother 10:1209\u20131218. https:\/\/doi.org\/10.1586\/ern.10.84","journal-title":"Expert Rev Neurother"},{"key":"8283_CR150","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1002\/jnr.23011","volume":"90","author":"Z Cai","year":"2012","unstructured":"Cai Z, Zhao B, Li K, Zhang L, Li C, Quazi SH, Tan Y (2012) Mammalian target of rapamycin: a valid therapeutic target through the autophagy pathway for alzheimer\u2019s disease? J Neurosci Res 90:1105\u20131118","journal-title":"J Neurosci Res"},{"key":"8283_CR151","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.exger.2014.12.002","volume":"68","author":"A Richardson","year":"2015","unstructured":"Richardson A, Galvan V, Lin AL, Oddo S (2015) How longevity research can lead to therapies for Alzheimer\u2019s disease: the rapamycin story. Exp Gerontol 68:51\u201358. https:\/\/doi.org\/10.1016\/j.exger.2014.12.002","journal-title":"Exp Gerontol"},{"key":"8283_CR152","doi-asserted-by":"publisher","first-page":"104834","DOI":"10.1016\/j.nbd.2020.104834","volume":"139","author":"AL Lin","year":"2020","unstructured":"Lin AL, Parikh I, Yanckello LM, White RS, Hartz AM, Taylor CE, Sanganahalli BG (2020) APOE genotype-dependent pharmacogenetic responses to rapamycin for preventing Alzheimer\u2019s disease. Neurobiol Dis 139:104834. https:\/\/doi.org\/10.1016\/j.nbd.2020.104834","journal-title":"Neurobiol Dis"},{"issue":"10","key":"8283_CR153","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1093\/gerona\/glab142","volume":"76","author":"H Wang","year":"2021","unstructured":"Wang H, Fu J, Xu X, Yang Z, Zhang T (2021) Rapamycin activates mitophagy and alleviates cognitive and synaptic plasticity deficits in a mouse model of Alzheimer\u2019s disease. J Gerontol 76(10):1707\u20131713. https:\/\/doi.org\/10.1093\/gerona\/glab142","journal-title":"J Gerontol"},{"issue":"2","key":"8283_CR154","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s11064-020-03160-6","volume":"46","author":"Y Ding","year":"2021","unstructured":"Ding Y, Liu H, Cen M, Tao Y, Lai C, Tang Z (2021) Rapamycin ameliorates cognitive impairments and Alzheimer\u2019s disease-like pathology with restoring mitochondrial abnormality in the hippocampus of streptozotocin-induced diabetic mice. Neurochem Res 46(2):265\u2013275. https:\/\/doi.org\/10.1007\/s11064-020-03160-6","journal-title":"Neurochem Res"},{"issue":"19","key":"8283_CR155","doi-asserted-by":"publisher","first-page":"4305","DOI":"10.1523\/JNEUROSCI.2144-20.2021","volume":"41","author":"CE Van Skike","year":"2021","unstructured":"Van Skike CE, Hussong SA, Hernandez SF, Banh AQ, DeRosa N, Galvan V (2021) mTOR attenuation with rapamycin reverses neurovascular uncoupling and memory deficits in mice modeling Alzheimer\u2019s disease. J Neurosci Res 41(19):4305\u20134320. https:\/\/doi.org\/10.1523\/JNEUROSCI.2144-20.2021","journal-title":"J Neurosci Res"},{"key":"8283_CR156","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1001\/jama.2019.22360","volume":"323","author":"MJ Armstrong","year":"2020","unstructured":"Armstrong MJ, Okun MS (2020) Diagnosis and treatment of Parkinson disease: a review. Am Med J 323:548\u2013560. https:\/\/doi.org\/10.1001\/jama.2019.22360","journal-title":"Am Med J"},{"key":"8283_CR157","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1503\/cmaj.151179","volume":"188","author":"P Rizek","year":"2016","unstructured":"Rizek P, Kumar N, Jog MS (2016) An update on the diagnosis and treatment of Parkinson disease. CMAJ 188:1157\u20131165. https:\/\/doi.org\/10.1503\/cmaj.151179","journal-title":"CMAJ"},{"key":"8283_CR158","doi-asserted-by":"publisher","first-page":"e9313","DOI":"10.1371\/journal.pone.0009313","volume":"5","author":"L Crews","year":"2010","unstructured":"Crews L, Spencer B, Desplats P, Patrick C, Paulino A, Rockenstein E, Hansen L, Adame A, Galasko D, Masliah E (2010) Selective molecular alterations in the autophagy pathway in patients with lewy body disease and in models of \u03b1-synucleinopathy. PLoS One 5:e9313. https:\/\/doi.org\/10.1371\/journal.pone.0009313","journal-title":"PLoS One"},{"key":"8283_CR159","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.biocel.2015.03.006","volume":"64","author":"S Gao","year":"2015","unstructured":"Gao S, Duan C, Gao G, Wang X, Yang H (2015) Alpha-synuclein overexpression negatively regulates insulin receptor substrate 1 by activating mTORC1\/S6K1 signaling. Int J Biochem Cell Biol 64:25\u201333. https:\/\/doi.org\/10.1016\/j.biocel.2015.03.006","journal-title":"Int J Biochem Cell Biol"},{"key":"8283_CR160","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pbb.2018.12.005","volume":"177","author":"AB Pupyshev","year":"2019","unstructured":"Pupyshev AB, Tikhonova MA, Akopyan AA, Tenditnik MV, Dubrovina NI, Korolenko TA (2019) Therapeutic activation of autophagy by combined treatment with rapamycin and trehalose in a mouse MPTP-induced model of Parkinson\u2019s disease. Pharmacol Biochem Behav 177:1\u20131. https:\/\/doi.org\/10.1016\/j.pbb.2018.12.005","journal-title":"Pharmacol Biochem Behav"},{"key":"8283_CR161","doi-asserted-by":"publisher","first-page":"465","DOI":"10.3785\/j.issn.1008-9292.2018.10.04","volume":"47","author":"F Zhu","year":"2018","unstructured":"Zhu F, Fan M, Xu Z, Cai Y, Chen Y, Yu S, Zeng L (2018) Neuroprotective effect of rapamycin against Parkinson\u2019s disease in mice. J Med Sci 47:465\u2013472. https:\/\/doi.org\/10.3785\/j.issn.1008-9292.2018.10.04","journal-title":"J Med Sci"},{"key":"8283_CR162","doi-asserted-by":"publisher","first-page":"e01575","DOI":"10.1128\/JVI.01575-20","volume":"94","author":"BR Sahoo","year":"2020","unstructured":"Sahoo BR, Pattnaikm A, Annamalai AS, Franco R, Pattnaik AK (2020) Mechanistic target of rapamycin signaling activation antagonizes autophagy to facilitate zika virus replication. J Virol 94:e01575\u2013e01520. https:\/\/doi.org\/10.1128\/JVI.01575-20","journal-title":"J Virol"},{"key":"8283_CR163","doi-asserted-by":"publisher","first-page":"e1006635","DOI":"10.1371\/journal.ppat.1006635","volume":"13","author":"SK Kuss-Duerkop","year":"2017","unstructured":"Kuss-Duerkop SK, Wang J, Mena I, White K, Metreveli G, Sakthivel R, Mata MA, Mu\u00f1oz-Moreno R, Chen X, Krammer F, Diamond MS (2017) Influenza virus differentially activates mTORC1 and mTORC2 signaling to maximize late stage replication. PLoS Pathog 13:e1006635. https:\/\/doi.org\/10.1371\/journal.ppat.1006635","journal-title":"PLoS Pathog"},{"key":"8283_CR164","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/nri3901","volume":"15","author":"T Weichhart","year":"2015","unstructured":"Weichhart T, Hengstschl\u00e4ger M, Linke M (2015) Regulation of innate immune cell function by mTOR. Nat Rev Immunol 15:599\u2013614. https:\/\/doi.org\/10.1038\/nri3901","journal-title":"Nat Rev Immunol"},{"key":"8283_CR165","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1097\/CCM.0b013e3182a2727d","volume":"42","author":"CH Wang","year":"2014","unstructured":"Wang CH, Chung FT, Lin SM, Huang SY, Chou CL, Lee KY, Lin TY, Kuo HP (2014) Adjuvant treatment with a mammalian target of rapamycin inhibitor, sirolimus, and steroids improves outcomes in patients with severe H1N1 pneumonia and acute respiratory failure. Crit Care Med 42:313\u2013321. https:\/\/doi.org\/10.1097\/CCM.0b013e3182a2727d","journal-title":"Crit Care Med"},{"key":"8283_CR166","doi-asserted-by":"publisher","first-page":"4783","DOI":"10.1002\/jcp.26276","volume":"233","author":"A Soltani","year":"2018","unstructured":"Soltani A, Bahreyni A, Boroumand N, Roshan MK, Khazaei M, Ryzhikov M, Soleimanpour S, Avan A, Hassanian SM (2018) Therapeutic potency of mTOR signaling pharmacological inhibitors in the treatment of proinflammatory diseases, current status, and perspectives. J Cell Physiol 233:4783\u20134790. https:\/\/doi.org\/10.1002\/jcp.26276","journal-title":"J Cell Physiol"},{"issue":"2","key":"8283_CR167","doi-asserted-by":"publisher","first-page":"e3110","DOI":"10.1002\/btpr.3110","volume":"37","author":"G Tatar","year":"2021","unstructured":"Tatar G, Ozyurt E, Turhan K (2021) Computational drug repurposing study of the RNA binding domain of SARS-CoV\u20102 nucleocapsid protein with antiviral agents. Biotechnol Prog 37(2):e3110. https:\/\/doi.org\/10.1002\/btpr.3110","journal-title":"Biotechnol Prog"},{"key":"8283_CR168","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1099\/jmm.0.001203","volume":"69","author":"R Pokhrel","year":"2020","unstructured":"Pokhrel R, Chapagain P, Siltberg-Liberles J (2020) Potential RNA-Dependent RNA polymerase inhibitors as prospective therapeutics against SARS-CoV-2. J Med Microbiol 69:864\u2013873. https:\/\/doi.org\/10.1099\/jmm.0.001203","journal-title":"J Med Microbiol"},{"key":"8283_CR169","doi-asserted-by":"publisher","first-page":"109282","DOI":"10.1016\/j.cbi.2020.109282","volume":"331","author":"A Husain","year":"2020","unstructured":"Husain A, Byrareddy SN (2020) Rapamycin as a potential repurpose drug candidate for the treatment of COVID-19. Chem. Biol Interact 331:109282. https:\/\/doi.org\/10.1016\/j.cbi.2020.109282","journal-title":"Biol Interact"},{"key":"8283_CR170","doi-asserted-by":"publisher","DOI":"10.3390\/ph14030217","author":"J Patocka","year":"2021","unstructured":"Patocka J, Kuca K, Oleksak P, Nepovimova E, Valis M, Novotny M, Klimova B (2021) Review rapamycin: drug repurposing in sars-cov-2 infection. Pharmaceuticals. https:\/\/doi.org\/10.3390\/ph14030217","journal-title":"Pharmaceuticals"},{"issue":"3","key":"8283_CR171","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/ijmm.2022.5088","volume":"49","author":"M Zurlo","year":"2022","unstructured":"Zurlo M, Nicoli F, Borgatti M, Finotti A, Gambari R (2022) Possible effects of sirolimus treatment on the long\u2013term efficacy of COVID\u201319 vaccination in patients with \u03b2\u2013thalassemia: a theoretical perspective. Int J Mol Med 49(3):1\u20135. https:\/\/doi.org\/10.3892\/ijmm.2022.5088","journal-title":"Int J Mol Med"},{"key":"8283_CR172","doi-asserted-by":"publisher","DOI":"10.1096\/fj.201600813R","author":"B Kumar","year":"2017","unstructured":"Kumar B, Arora S, Ahmed S, Banerjea AC (2017) Hyperactivation of mammalian target of rapamycin complex 1 by HIV-1 is necessary for virion production and latent viral reactivation. FASEB J. https:\/\/doi.org\/10.1096\/fj.201600813R","journal-title":"FASEB J"},{"key":"8283_CR173","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.3389\/fimmu.2017.01358","volume":"8","author":"A Venuti","year":"2017","unstructured":"Venuti A, Pastori C, Lopalco L (2017) The role of natural antibodies to CC chemokine receptor 5 in HIV infection. Front immunol 8:1358. https:\/\/doi.org\/10.3389\/fimmu.2017.01358","journal-title":"Front immunol"},{"key":"8283_CR174","doi-asserted-by":"publisher","first-page":"10411","DOI":"10.1073\/pnas.1834278100","volume":"100","author":"A Heredia","year":"2003","unstructured":"Heredia A, Amoroso A, Davis CLEN, Le N, Reardon E, Dominique JK, Klingebiel E, Gallo RC, Redfield RR (2003) Rapamycin causes down-regulation of CCR5 and accumulation of anti-HIV \u03b2-chemokines: an approach to suppress R5 strains of HIV-1. PNAS 100:10411\u201310416. https:\/\/doi.org\/10.1073\/pnas.1834278100","journal-title":"PNAS"},{"key":"8283_CR175","doi-asserted-by":"publisher","first-page":"20476","DOI":"10.1073\/pnas.0810843106","volume":"105","author":"A Heredia","year":"2008","unstructured":"Heredia A, Latinovic O, Gallo RC, Melikyan G, Reitz M, Le N, Redfield RR (2008) Reduction of CCR5 with low-dose rapamycin enhances the antiviral activity of vicriviroc against both sensitive and drug-resistant HIV-1. Proc Natl Aca Sci 105:20476\u201320481. https:\/\/doi.org\/10.1073\/pnas.0810843106","journal-title":"Proc Natl Aca Sci"},{"issue":"6","key":"8283_CR176","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1007\/BF00166931","volume":"43","author":"YR Cheng","year":"1995","unstructured":"Cheng YR, Fang A, Demain AL (1995) Effect of amino acids on rapamycin biosynthesis by Streptomyces hygroscopicus. Appl Microbiol Biotechnol 43(6):1096\u20131098. https:\/\/doi.org\/10.1007\/BF00166931","journal-title":"Appl Microbiol Biotechnol"},{"issue":"9","key":"8283_CR177","doi-asserted-by":"publisher","first-page":"4197","DOI":"10.5958\/0974-360X.2019.00722.4","volume":"12","author":"MA Mohamed","year":"2019","unstructured":"Mohamed MA, Elkhateeb WA, Taha MA, Daba GM (2019) New strategies in optimization of rapamycin production by Streptomyces hygroscopicus ATCC 29253. Res J Pharm Technol 12(9):4197\u20134204. https:\/\/doi.org\/10.5958\/0974-360X.2019.00722.4","journal-title":"Res J Pharm Technol"},{"issue":"10","key":"8283_CR178","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.4014\/jmb.1403.03024","volume":"24","author":"YH Kim","year":"2014","unstructured":"Kim YH, Park BS, Bhatia SK, Seo HM, Jeon JM, Kim HJ, Yang YH (2014) Production of rapamycin in Streptomyces hygroscopicus from glycerol-based media optimized by systemic methodology. J Microbiol Biotechnol 24(10):1319\u20131326","journal-title":"J Microbiol Biotechnol"},{"issue":"6","key":"8283_CR179","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1080\/10826068.2012.759969","volume":"43","author":"RP Baby","year":"2013","unstructured":"Baby RP, Battula SK, Rao AB, Gunja M, Narasu ML (2013) Improvement of microbial strain and fermentation process of rapamycin biosynthesis. Prep Biochem Biotechnol 43(6):539\u2013550. https:\/\/doi.org\/10.1080\/10826068.2012.759969","journal-title":"Prep Biochem Biotechnol"},{"issue":"3","key":"8283_CR180","doi-asserted-by":"publisher","first-page":"296","DOI":"10.4014\/mbl.2001.01002","volume":"48","author":"HTH La","year":"2020","unstructured":"La HTH, Nguyen TKN, Dinh HT, Nguyen QMH, Nguyen MH (2020) Effects of glycerol and shikimic acid on rapamycin production in Streptomyces rapamycinicus. Microbiol Biotechnol Lett 48(3):296\u2013302. https:\/\/doi.org\/10.4014\/mbl.2001.01002","journal-title":"Microbiol Biotechnol Lett"},{"issue":"4","key":"8283_CR181","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1128\/AEM.71.4.1971-1976.2005","volume":"71","author":"FV Ritacco","year":"2005","unstructured":"Ritacco FV, Graziani EI, Summers MY, Zabriskie TM, Yu K, Bernan VS, Greenstein M (2005) Production of novel rapamycin analogs by precursor-directed biosynthesis. Appl Environ Microbiol 71(4):1971\u20131976. https:\/\/doi.org\/10.1128\/AEM.71.4.1971-1976.2005","journal-title":"Appl Environ Microbiol"},{"issue":"3","key":"8283_CR182","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1067\/mcp.2001.118022","volume":"70","author":"JM Kovarik","year":"2001","unstructured":"Kovarik JM, Hsu CH, McMahon L, Berthier S, Rordorf C (2001) Population pharmacokinetics of everolimus in de novo renal transplant patients: impact of ethnicity and comedications. Clin Pharm Therap 70(3):247\u2013254. https:\/\/doi.org\/10.1067\/mcp.2001.118022","journal-title":"Clin Pharm Therap"},{"issue":"8","key":"8283_CR183","doi-asserted-by":"publisher","first-page":"3050","DOI":"10.1016\/j.transproceed.2010.07.083","volume":"42","author":"F Sanchez","year":"2010","unstructured":"Sanchez F, Ruiz JC, Perez-Flores I, Alamilo CG, Romero NC, Arias M (2010) Comparative analysis of adverse events requiring suspension of mTOR inhibitors: Everolimus versus Sirolimus. Transpl Proc 42(8):3050\u20133052. https:\/\/doi.org\/10.1016\/j.transproceed.2010.07.083","journal-title":"Transpl Proc"},{"issue":"5","key":"8283_CR184","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1046\/j.1365-2125.1999.00085.x","volume":"48","author":"HH Neumayer","year":"1999","unstructured":"Neumayer HH, Paradis K, Korn A, Jean C, Fritsche L, Budde K, Appel-Dingemanse S (1999) Entry-into-human study with the novel immunosuppressant SDZ RAD in stable renal transplant recipients. Br J Clin Pharmacol 48(5):694. https:\/\/doi.org\/10.1046\/j.1365-2125.1999.00085.x","journal-title":"Br J Clin Pharmacol"},{"issue":"22","key":"8283_CR185","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1056\/NEJMoa066838","volume":"356","author":"G Hudes","year":"2007","unstructured":"Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Motzer RJ (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. NEJM 356(22):2271\u20132281. https:\/\/doi.org\/10.1056\/NEJMoa066838","journal-title":"NEJM"},{"issue":"4","key":"8283_CR186","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s00228-010-0895-1","volume":"67","author":"MC Ostojic","year":"2011","unstructured":"Ostojic MC, Perisic Z, Sagic D, Jung R, Zhang YL, Bendrick-Peart J, Christians U (2011) The pharmacokinetics of Biolimus A9 after elution from the BioMatrix II stent in patients with coronary artery disease: the Stealth PK study. Eur J Clin Pharmacol 67(4):389\u2013398. https:\/\/doi.org\/10.1007\/s00228-010-0895-1","journal-title":"Eur J Clin Pharmacol"},{"issue":"8","key":"8283_CR187","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1001\/jama.2012.10065","volume":"308","author":"L R\u00e4ber","year":"2012","unstructured":"R\u00e4ber L, Kelbaek H, Ostojic M, Baumbach A, Heg D, Tueller D (2012) Effect of biolimus-eluting stents with biodegradable polymer vs bare-metal stents on cardiovascular events among patients with acute myocardial infarction: the COMFORTABLE AMI randomized trial. JAMA 308(8):777\u2013787. https:\/\/doi.org\/10.1001\/jama.2012.10065","journal-title":"JAMA"},{"issue":"7","key":"8283_CR188","doi-asserted-by":"publisher","first-page":"827","DOI":"10.2217\/fon.11.5","volume":"7","author":"JE Dancey","year":"2011","unstructured":"Dancey JE, Monzon J (2011) Ridaforolimus: a promising drug in the treatment of soft-tissue sarcoma and other malignancies. Future Oncol 7(7):827\u2013839. https:\/\/doi.org\/10.2217\/fon.11.5","journal-title":"Future Oncol"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-023-08283-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-023-08283-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-023-08283-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T10:41:38Z","timestamp":1744195298000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-023-08283-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,25]]},"references-count":188,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["8283"],"URL":"https:\/\/doi.org\/10.1007\/s11033-023-08283-x","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,25]]},"assertion":[{"value":"26 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}